FDA Suspends Ban on Juul E-cigarette Sales

Jul.13.2022
FDA Suspends Ban on Juul E-cigarette Sales
The FDA temporarily suspends ban on Juul sales for extra review, but concerns over health risks persist.

The US Food and Drug Administration (FDA) has suspended its ban on the sale of Juul Labs' e-cigarettes, stating that additional scrutiny is required for the company's marketing application. Following Juul's appeal for an urgent review of the FDA's order, the federal appeals court decided to temporarily freeze the FDA's ban a few weeks ago.


However, this once flourishing company still remains in a difficult situation: the US Food and Drug Administration has only temporarily halted the re-evaluation ban, it has not been lifted.


Juul has been in the limelight in part due to its prominent position in the e-cigarette industry. However, as the company faces potential extinction, it may become the first casualty while the rest of the e-cigarette industry comes under increasing government scrutiny.


Dr. Zubair Karim, an assistant professor in the Department of Interdisciplinary Health Sciences at Augusta University, conducted research on Juul e-cigarettes and their potential to increase the risk of blood clots and other complications in users.


According to Karim, thrombosis is the partial or complete blockage of blood vessels, whether it occurs in veins or arteries, which restricts the natural flow of blood.


According to the location of blood clot formation, there are several potential complications. The most severe issues include stroke, heart attack, and a serious respiratory condition known as pulmonary embolism. Without prompt treatment, these conditions can be life-threatening. However, by focusing on lifestyle changes such as increasing physical activity, quitting smoking, losing weight, maintaining a balanced diet, avoiding junk food, and managing other health conditions, it is possible to prevent the disease from advancing.


As a ban on Juul products looms, it could lead to a ban on other companies' electronic cigarette products.


Karim stated, "This is the first step in banning e-cigarettes, and the FDA has taken an important and bold move.


Gradually, this will pave the way for the banning of other e-cigarette products. Juul and other products are no different, but Juul is becoming increasingly popular among our younger generation. Many localities and states have recently begun implementing laws banning the use of e-cigarettes, although some states with comprehensive smoke-free laws will still allow the use of e-cigarettes in bars and restaurants while prohibiting their use in other indoor venues.


For years, electronic cigarettes and their devices have been considered a "safer" alternative to traditional cigarettes, but their flavors and packaging have attracted children, and there are renewed efforts to study their possible side effects.


Looking at the long-term effects, both smoking and vaping have similar side effects and pose serious health risks. Scientists do not fully understand the long-term impact of vaping on health, but studies show that electronic cigarettes are not a safe alternative to smoking," said Karim.


In recent years, it has been observed that electronic cigarettes are becoming increasingly popular among young people. Additionally, electronic cigarettes contain high doses of nicotine, which is known to slow the development of fetuses, children, and adolescents' brains. Furthermore, electronic cigarettes involve inhaling aerosols that contain multiple chemicals, including those used for flavoring via electronic cigarettes or other devices. Additionally, the liquid produced in electronic cigarettes can be hazardous if swallowed, inhaled, or applied topically to the skin for both adults and children.


Despite this, e-cigarettes still contain harmful chemicals such as diacetyl, carcinogens, heavy metals, volatile organic compounds, and toxic chemicals not found in traditional cigarettes. In summary, the long-term toxic effects of e-cigarette use on overall health are similar to those of traditional cigarettes.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Philip Morris Korea Names Lee Hong-seok as New CEO Effective May 1
Philip Morris Korea Names Lee Hong-seok as New CEO Effective May 1
Philip Morris Korea said on April 29 that it has appointed Lee Hong-seok, head of its smoke-free products division, as its new chief executive officer, with his term beginning on May 1. Yoon Hee-kyung, who took office in 2023, will step down after about three years in the role.
Apr.30 by 2FIRSTS.ai
Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Technology reported financial results on May 7, 2026, for the third quarter of fiscal 2026, covering the three months ended March 31, 2026. Revenue was $18.7 million, compared with $26.2 million in the third quarter of fiscal 2025 and $20.3 million in the prior quarter. Gross profit was $2.0 million, with gross margin of 10.7%. Net loss was $9.5 million, or $0.17 per share. The company said it held $18.0 million in cash as of March 31, 2026, up $468,000 sequentially.
May.08 by 2FIRSTS.ai
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
mperial Brands’ HY26 results point to a more selective NGP transition. The company is using cash flow from traditional tobacco to fund targeted investments in modern oral nicotine, heated tobacco and reusable vaping systems. Its decision to exit the legacy myblu vaping business in the U.S., while expanding Zone nicotine pouches. In Europe, Imperial’s NGP growth is being driven by a multi-category portfolio including blu, Pulze and Zone/Skruf.
Special Report
May.12
Fifth Circuit Hears Challenge to FDA’s Standard for Reviewing Flavored Vape Applications
Fifth Circuit Hears Challenge to FDA’s Standard for Reviewing Flavored Vape Applications
A three-judge panel of the U.S. Court of Appeals for the Fifth Circuit heard oral arguments on Tuesday in a case brought by seven small vape-liquid companies challenging the Food and Drug Administration’s denial of marketing authorization for their flavored electronic nicotine products.
Apr.30 by 2FIRSTS.ai
FDA Says It Will Not Take Enforcement Action Against Zone Nicotine Pouches Until Lawsuit Is Resolved
FDA Says It Will Not Take Enforcement Action Against Zone Nicotine Pouches Until Lawsuit Is Resolved
The U.S. Food and Drug Administration has told vape manufacturer Fontem US that it does not presently intend to take enforcement action against the company’s Zone nicotine pouches while litigation over the agency’s handling of the application remains unresolved.
Apr.07 by 2FIRSTS.ai
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands reported first-quarter 2026 results on May 7, covering the period ended March 31, 2026. Total consolidated net sales were $124.3 million, up 16.8% year on year. Gross profit was $68.3 million, up 14.6%, while net income fell 19.0% to $11.7 million. Adjusted EBITDA declined 6.5% to $25.9 million.
May.08 by 2FIRSTS.ai